Cefpodoxime-Induced Hyperprolactinemic Galactorrhea
Authors: Vishal Khurana
Journal: Annals of Internal Medicine (2010)

Letters19 January 2010Cefpodoxime-Induced Hyperprolactinemic GalactorrheaVishal Khurana, MBBS, MD and Indrajeet Singh GambhirVishal Khurana, MBBS, MDFrom Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.Search for more papers by this author and Indrajeet Singh GambhirFrom Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-2-201001190-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Cefpodoxime has not been reported to cause galactorrhea.Objective: To describe an association between cefpodoxime and galactorrhea.Case Report: A 40-year-old, ambulatory woman reported passage of milk from both breasts for 2 days. She had been taking cefpodoxime, 200 mg twice daily for 4 days, to treat fever and cough. She was not taking any of the drugs or herbs known to cause galactorrhea. She reported no sexual activity in the past 10 days. She reported no visual disturbance or symptoms of increased intracranial pressure. A physical examination revealed no other abnormality. Her fever and cough resolved, but she ...References1. da Silva OP, Knoppert DC. Domperidone for lactating women. CMAJ. 2004;171:725-6. [PMID: 15451832] CrossrefMedlineGoogle Scholar2. Windgassen K, Wesselmann U, Schulze Mönking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology. 1996;33:142-6. [PMID: 8776743] CrossrefMedlineGoogle Scholar3. Katznelson L, Klibanski A. Hyperprolactinemia: physiology and clinical approach.. In: Krisht AF, Tindall GT, eds. Pituitary Disorders: Comprehensive Management. 1st ed. Baltimore: Lippincott Williams Wilkins; 1999:189-98. Google Scholar4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. [PMID: 7249508] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHyperprolactinemic Galactorrhea Associated With Cefpodoxime in a Patient With Recurrent Depressive Disorder on Venlafaxine MonotherapyCurrent awareness: Pharmacoepidemiology and drug safetyWarfarin-Induced Skin Necrosis; Antibiotics and Vanishing Bile Duct Syndrome; Brugada Syndrome Unmasked by Lithium; Adalimumab-Induced Autoimmune Hepatitis; Gemfibrozil-Induced Myositis; Cefpodoxime-Induced Hyperprolactinemic Galactorrhea; Olanzapine-Induced Tardive Oculogyric Crisis 19 January 2010Volume 152, Issue 2Page: 136KeywordsAntipsychoticsDrugsFeversMilkProlactinStomachThyroid-stimulating hormoneUrineUrticariaVomiting ePublished: 19 January 2010 Issue Published: 19 January 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...